Skip to main content
Fig. 5 | BMC Complementary Medicine and Therapies

Fig. 5

From: Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response

Fig. 5

The cantharidin treatment affects chemokine related immune response. (A, B) GO functional annotation shows that cantharidin treatment is positively associated with chemokine biosynthetic and metabolic processes based on GSEA analysis. (C) Venn diagram shows that the differently expressed genes of chemokine and chemokine receptor in the cantharidin treated HepG2 cell. (D, E) The heatmap shows the expression of chemokine (D), and chemokine receptor (E) in the differently expressed genes of cantharidin treated HepG2 cell. (F) The heatmap shows the association of chemokine and chemokine receptor with EZH2 in LIHC, * P < 0.05 was regarded as statistically significant

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us